I believe the primary signal that is being sought in the small trials is the actual extent of the ‘Brekken Effect’ in human patients. I think Dr. Brekken,TexSW, is a straight shooter when he makes claims that come from his lab work. We need to see how it actually translates in trials.
Being a straight shooter has nothing to do with it. One needs to recognize that results from cell lines and mouse models very frequently don't replicate in human trials.
Market Data 
Markets 
AI
